# SampleID	BarcodeSequence	LinkerPrimerSequence	ReversePrimer	run_prefix	pub_id	Sex	Visit	visitRank	RXCode	Description
Sample-78	TTACGC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-281	Female	2	1	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-79	TTAGGT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-281	Female	9	2	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-80	TTCTCC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-281	Female	12	3	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-81	TTCCAC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-208	Female	12	1	T2	NYVAC (2) & AIDSVAX B/E mo(0,1,3,6)
Sample-82	TTGTAC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-236	Male	9	1	T3	DNA & placebo (2) mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-84	TATCAC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-019	Male	9	1	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-85	TATGCC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-019	Male	12	2	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-86	TAATCC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-290	Female	12	1	T4	DNA & placebo & AIDSVAX B/E mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-87	TACTAC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-003	Female	2	1	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-88	TACGTT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-003	Female	9	2	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-89	TCTTAC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-021	Male	9	1	T2	NYVAC (2) & AIDSVAX B/E mo(0,1,3,6)
Sample-90	TCAACC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-021	Male	12	2	T2	NYVAC (2) & AIDSVAX B/E mo(0,1,3,6)
Sample-91	TCACTC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-247	Female	12	1	T3	DNA & placebo (2) mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-92	TCGGTT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-175	Female	12	1	T4	DNA & placebo & AIDSVAX B/E mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-93	TGTTCT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-040	Male	2	1	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-94	TGAAGT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-040	Male	12	2	T1	NYVAC (2) & placebo mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-95	TGACTT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-063	Female	2	1	C4	placebo (2) & AIDSVAX B/E placebo mo(0,1,3,6)
Sample-96	TGACAC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-063	Female	9	2	C4	placebo (2) & AIDSVAX B/E placebo mo(0,1,3,6)
Sample-97	TGCATT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-063	Female	12	3	C4	placebo (2) & AIDSVAX B/E placebo mo(0,1,3,6)
Sample-98	TGGAAC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	096-092	Female	9	1	T3	DNA & placebo (2) mo(0,1) + NYVAC (2) & AIDSVAX B/E mo(3,6)
Sample-E	ATGGAT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	NA		NA	NA		
Sample-F	AATAGC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	NA		NA	NA		
db2	AACTTC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	NA		NA	NA		
db3	AACACC	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	NA		NA	NA		
pyro-ntc-3	AACCGT	GCGGACTACCVGGGTATCTAAT	GCACTCCTRCGGGAGGCAGCAG,GCACACCTACGGGTGGCTGC,GCACACCTACGGGTGGCAGC	JH5DUPV01	NA		NA	NA		
